Fibromyalgia, milnacipran and experimental pain modulation: study protocol for a double blind randomized controlled...

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Medicine

Background:

• Fibromyalgia prevalence is rising globally, presenting challenges in pain management.
• Current treatments involve drug and non-drug therapies, with milnacipran showing potential for central pain modulation.
• This study investigates if pain inhibitory control performance predicts milnacipran's effectiveness in fibromyalgia patients.

Purpose of the Study:

• To evaluate the efficacy of milnacipran in treating fibromyalgia.
• To determine if conditioned pain modulation predicts milnacipran's therapeutic effect.
• To assess milnacipran's impact on descending pain pathways and cognitive function.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 48 women with fibromyalgia.
• Primary endpoint: Conditioned pain modulation assessed via thermal stimuli and a numeric pain rating scale, measured pre- and post-treatment.
• Secondary outcomes: Predictability of descending pain pathways, tolerance, and cognitive function; data analyzed using mixed models.

Main Results:

• The trial aims to estimate milnacipran's beneficial effects on pain and descending pain pathways.
• It will assess the predictive value of the pain modulatory system's performance for milnacipran efficacy.
• Results will inform clinical practice regarding milnacipran prescription for fibromyalgia.

Conclusions:

• A predictive psychophysical test could guide milnacipran treatment decisions.
• This approach may prevent unnecessary prescriptions and therapeutic failures in fibromyalgia patients.
• Optimizing treatment selection can improve patient outcomes for chronic widespread pain.